Structure Therapeutics Selects Lead Oral Amylin Receptor Agonist ACCG-2671 for Obesity Treatment

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company based in San Francisco and traded on NASDAQ under the symbol GPCR, has announced the selection of ACCG-2671 as its leading oral small molecule amylin receptor agonist. This advancement marks an important step in their development of treatments for metabolic diseases, focusing on obesity and related conditions. ACCG-2671, recognized for its potent target engagement and robust weight loss capability in preclinical studies, is designed as a Dual Amylin and Calcitonin Receptor Agonist (DACRA). The drug candidate is slated to enter Phase 1 clinical trials by the end of 2025.

Amylin, a hormone secreted alongside insulin by the pancreas, plays a significant role in managing blood glucose levels and energy balance. It is a promising target for therapeutic interventions in obesity due to its ability to reduce food intake and delay gastric emptying. Structure Therapeutics is leveraging this potential by developing ACCG-2671 as an oral therapeutic, which could revolutionize treatment approaches by offering a non-invasive administration route and the potential for widespread use.

Raymond Stevens, Ph.D., the Founder and CEO of Structure Therapeutics, emphasized the importance of amylin-based therapies in the evolving landscape of obesity treatments. He highlighted that these therapies have the potential for significant weight loss, favorable safety profiles, and the preservation of lean muscle mass. As an oral small molecule, ACCG-2671 offers scalability and combinability, enhancing patient access to effective weight loss treatments. Stevens noted that, alongside ACCG-2671, the company is also developing GSBR-1290, a GLP-1 oral small molecule, as part of their strategy to provide monotherapies and foundational components for fixed-dose combinations.

Preclinical evaluations of ACCG-2671 have shown promising results, demonstrating potent activities targeting both the amylin and calcitonin receptors. The compound has also exhibited strong in vivo efficacy and a pharmacokinetic and safety profile that supports once-daily oral dosing in humans. Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics, underscored the significance of these findings, suggesting that ACCG-2671 could offer a differentiated and meaningful oral treatment option for obesity and related disorders. The rapid development of ACCG-2671 was made possible through the company's GPCR structure-based drug discovery platform, which continues to produce a series of amylin-based drug candidates to maintain their leadership in this innovative field.

Structure Therapeutics is exploring both DACRAs and Selective Amylin Receptor Agonists (SARAs), as both types of treatments have demonstrated potential for managing obesity and chronic weight issues. ACCG-2671, as a DACRA, is being evaluated for its effectiveness either as a standalone treatment or in combination with GLP-1R agonists, aiming to address obesity and its associated diseases comprehensively.

The company is committed to advancing its technology platform and pipeline, focusing on chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Through the development of small molecule compounds, Structure Therapeutics aims to overcome the scalability challenges associated with biologic and peptide therapies, making treatment more accessible to a broader patient population worldwide. This strategic approach underscores their dedication to innovation and improving health outcomes in metabolic disease treatment.